During cancer treatment
Reviewed by executive management. September 16, 2026. Scientific review pending.
If you are receiving chemotherapy, immunotherapy or another cancer treatment, tell your oncology team about every prescription medicine, nonprescription medicine and supplement you use or are considering. Do not start a cannabinoid product without discussing it with the team responsible for your cancer treatment.
Important evidence context. Micelle 60 and FDA-approved prescription cannabidiol are separate products. No clinical, pharmacokinetic, exposure, efficacy, safety or comparability bridge has been established between them. Micelle 60 is not FDA approved, and no clinical benefit or product-specific safety profile has been established for it.
How we review this information
These pages are reviewed and approved by executive management and have been submitted to our Chief Scientific Officer for scientific review. Each page will show her name and the date once she has signed it. Each claim-bearing page identifies its sources, evidence limitations and the date the evidence was last checked. Draft or incomplete pages remain unpublished.
Approved uses are specific
FDA-approved prescription drugs containing dronabinol or nabilone are indicated for nausea and vomiting associated with cancer chemotherapy in specified patients whose symptoms have not responded adequately to conventional anti-nausea treatment. They are not CBD products, do not treat cancer and are not Micelle 60. ASCO concludes that cannabis or cannabinoids may improve refractory chemotherapy-induced nausea and vomiting when added to guideline-concordant antiemetic treatment. [1, 12]Source: U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD).; Braun IM, et al. Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline. Journal of Clinical Oncology. 2024;42(13):1575–1593. doi:10.1200/JCO.23.02596. Last checked: .
Cancer-directed use
Laboratory and animal findings do not show that a product treats cancer in people. ASCO recommends against cannabis or cannabinoids as cancer-directed treatment outside a clinical trial. Human evidence has not established that CBD treats cancer or slows progression. [12]Source: Braun IM, et al. Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline. Journal of Clinical Oncology. 2024;42(13):1575–1593. doi:10.1200/JCO.23.02596. Last checked: .
Pain, appetite and weight
Whether cannabis or cannabinoids improve cancer pain, appetite, weight loss or other supportive-care outcomes remains uncertain. No benefit has been established for Micelle 60. [12]Source: Braun IM, et al. Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline. Journal of Clinical Oncology. 2024;42(13):1575–1593. doi:10.1200/JCO.23.02596. Last checked: .
Interactions
The prescription-cannabidiol label documents clinically relevant interactions, including increased everolimus exposure at prescription doses. Other label-supported examples include clobazam, valproate, stiripentol and clopidogrel. These data do not quantify Micelle 60’s risk. The oncology pharmacist or treating team should review the exact treatment regimen and product. [2]Source: Jazz Pharmaceuticals, Inc. EPIDIOLEX® (cannabidiol) oral solution: Full Prescribing Information. Revised May 2026. DailyMed, U.S. National Library of Medicine. Last checked: .
Immunotherapy
Observational studies in people receiving immune-checkpoint inhibitors have reported conflicting associations between cannabis use and treatment response or survival. These studies were not randomized, cannot establish causation, and did not study isolated 60 mg CBD or Micelle 60. No randomized evidence establishes safety with immune-checkpoint inhibitors. Discuss use with the oncologist before starting. [13–16]Source: Braun IM, et al. Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline. Journal of Clinical Oncology. 2024;42(13):1575–1593. doi:10.1200/JCO.23.02596.; Taha T, et al. Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. The Oncologist. 2019;24(4):549–554. doi:10.1634/theoncologist.2018-0383.; Bar-Sela G, et al. Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers. 2020;12(9):2447. doi:10.3390/cancers12092447. With 2022 correction.; Waissengrin B, et al. The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: A sigh of relief? European Journal of Cancer. 2023;180:52–61. doi:10.1016/j.ejca.2022.11.022.; Hadid T, et al. Association between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitors. Therapeutic Advances in Vaccines and Immunotherapy. 2024;12:25151355241309095. doi:10.1177/25151355241309095. Last checked: .
Bleeding
Micelle 60’s effect on bleeding risk is unknown. If platelet counts are low, or anticoagulant or antiplatelet medicines are used, ask the oncology team to review the product and medicine list.
Sources: [1–2, 12–16]. Evidence last checked September 16, 2026.Source: U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD).; Jazz Pharmaceuticals, Inc. EPIDIOLEX® (cannabidiol) oral solution: Full Prescribing Information. Revised May 2026. DailyMed, U.S. National Library of Medicine.; Braun IM, et al. Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline. Journal of Clinical Oncology. 2024;42(13):1575–1593. doi:10.1200/JCO.23.02596.; Taha T, et al. Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. The Oncologist. 2019;24(4):549–554. doi:10.1634/theoncologist.2018-0383.; Bar-Sela G, et al. Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers. 2020;12(9):2447. doi:10.3390/cancers12092447. With 2022 correction.; Waissengrin B, et al. The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: A sigh of relief? European Journal of Cancer. 2023;180:52–61. doi:10.1016/j.ejca.2022.11.022.; Hadid T, et al. Association between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitors. Therapeutic Advances in Vaccines and Immunotherapy. 2024;12:25151355241309095. doi:10.1177/25151355241309095. Last checked: .